We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 1, 2008
Last Update Posted: January 4, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Children's Hospital and Health System Foundation, Wisconsin
Information provided by:
Medical College of Wisconsin
Blinded study using oral gabapentin in load pre-operative (15mg/kg) and maintenance 5mg/kg three times a day (TID) for 5 days or discharge, Patient Controlled Analgesia (PCA) morphine and placebo group with similar pills, also PCA morphine. The goal is to measure morphine usage and incidence of morphine side effects (pruritis, days foley, days to first stool, sedation, pain scores, PCA use).

Condition Intervention
Postoperative Pain Drug: Gabapentin Drug: Placebo Drug: Morphine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients

Resource links provided by NLM:

Further study details as provided by Medical College of Wisconsin:

Primary Outcome Measures:
  • Amount of Morphine Consumed (mg/kg/hr) [ Time Frame: PARU (Postanesthesia Recovery Unit - participants typically remain in PARU for 1 hour) ]
    Patients are taken to the PARU immediately after surgery, and typically remain for a period of 1 hour.

  • Amount of Morphine Consumed (mg/kg/hr) [ Time Frame: Day 1 ]
  • Amount of Morphine Consumed (mg/kg/hr) [ Time Frame: Day 2 ]

Secondary Outcome Measures:
  • Side Effect Occurrence [ Time Frame: First 10 days after surgery ]
    The number of episodes of/occurrence of side effects was monitored in both groups.

Enrollment: 63
Study Start Date: June 2006
Study Completion Date: May 2009
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: Gabapentin
oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
Other Name: Neurontin
Drug: Morphine
Administered as needed
Placebo Comparator: 2
Placebo Comparator -- pill matched in appearance to gabapentin
Drug: Placebo Drug: Morphine
Administered as needed

Detailed Description:

Healthy, American Society of Anesthesia (ASA) 1-2 Idiopathic Scoliosis patients for spinal fusion.

Blinded, drug only known by hospital pharmacist. Study group 1- Gabapentin 15mg/kg with premed, 5/kg TID for 5 days of discharge, standard PCA morphine with dose and basal Study Group 2- Capsules resembling neurontin, with standard PCA morphine

No remifentanil, clonidine, ketamine

N=60 First patient enrolled 6/06 Last patient enrolled 7/15/08


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   9 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA 1-2, Idiopathic Scoliosis

Exclusion Criteria:

  • ASA 3 or greater
  • Neuromuscular scoliosis
  • On narcotics baseline
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00726999

Sponsors and Collaborators
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin
Principal Investigator: Lynn M Rusy, MD Medical College of Wisconsin
  More Information

Responsible Party: Dr. Lynn M. Rusy, Medical College of Wisconsin Anesthesia Department
ClinicalTrials.gov Identifier: NCT00726999     History of Changes
Other Study ID Numbers: 06/71,GC 138
First Submitted: July 30, 2008
First Posted: August 1, 2008
Results First Submitted: August 19, 2010
Results First Posted: December 30, 2010
Last Update Posted: January 4, 2011
Last Verified: January 2011

Keywords provided by Medical College of Wisconsin:
Pediatric Spinal Fusion
Narcotic Use

Additional relevant MeSH terms:
Pain, Postoperative
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
gamma-Aminobutyric Acid
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents